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Introduction:  Left  ventricular  (LV) thrombus  formation  is  a feared  complication  of myocardial  infarc-
tion  (MI).  We  assessed  the  prevalence  of  LV  thrombus  in  ST-segment  elevated  MI  patients  treated  with
percutaneous  coronary  intervention  (PCI)  and  compared  the diagnostic  accuracy  of  transthoracic  echocar-
diography  (TTE)  to  cardiovascular  magnetic  resonance  imaging  (CMR).  Also,  we  evaluated  the course  of
LV  thrombi  in the  modern  era  of  primary  PCI.
Methods:  200  patients  with  primary  PCI  underwent  TTE  and  CMR,  at baseline  and  at  4  months  follow-
up.  Studies  were  analyzed  by two  blinded  examiners.  Patients  were  seen  at 1, 4, 12,  and  24  months  for
assessment  of clinical  status  and  adverse  events.
Results: On CMR  at baseline,  a thrombus  was found  in  17 of  194  (8.8%)  patients.  LV  thrombus  resolution
occurred  in 15  patients.  Two  patients  had  persistence  of  LV  thrombus  on  follow-up  CMR.  On  CMR  at  four
months,  a thrombus  was  found  in  an  additional  12  patients.  In multivariate  analysis,  thrombus  formation
on  baseline  CMR  was  independently  associated  with,  baseline  infarct  size  (g)  (B  = 0.02,  SE  =  0.02,  p <  0.001).
Routine  TTE  had  a sensitivity  of  21–24%  and  a speciﬁcity  of  95–98%  compared  to CMR  for  the  detection  of
LV  thrombi.  Intra-  and  interobserver  variation  for  detection  of  LV  thrombus  were  lower  for CMR  (  =  0.91
and   =  0.96)  compared  to TTE  (  =  0.74  and    = 0.53).
Conclusion:  LV  thrombus  still occurs  in  a substantial  amount  of  patients  after  PCI-treated  MI, especially  in
larger  infarct  sizes.  Routine  TTE  had  a  low  sensitivity  for the  detection  of  LV  thrombi  and  the  interobserver
.variation  of  TTE  was  large
. Introduction
Mortality due to acute myocardial infarction (MI) has decreased
ince the introduction of primary percutaneous coronary interven-
ion (PCI) [1].  Nevertheless, post infarct complications are still a
ajor cause of morbidity and mortality. One of the most feared
omplications is the occurrence of thrombo-embolic events in
atients with left ventricular (LV) thrombus [2,6]. To date, no
andomized trials have evaluated the efﬁcacy of anticoagulation
herapy in preventing embolization in this group of patients. How-
ver, observational studies conducted in the pre-thrombolytic and
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thrombolytic era, provide support for long term anticoagulation
with vitamin K antagonist [3–5]. This is reﬂected in the ESC and
ACC/AHA guidelines recommending vitamin K antagonist therapy
in patients with LV thrombus after MI  for at least 3–6 months and
even indeﬁnitely in patients without increased risk of bleeding
[7,8].
Nowadays, ST-segment elevated myocardial infarction (STEMI)
patients undergo primary PCI and receive long term dual
anti-platelet therapy (including aspirin and a P2Y12 inhibitor).
Consequently, patients with LV thrombus or at increased risk of LV
thrombus formation after an MI  are frequently treated with vitamin
K antagonist in addition to dual anti-platelet therapy and therefore
subjected to an increased bleeding risk [9].  Adequate diagnosis and
Open access under the Elsevier OA license.follow-up of LV thrombus formation is therefore essential.
We performed a study to address the following issues: (1) assess
the prevalence of LV thrombus in patients after STEMI treated
with primary PCI and dual anti-platelet therapy, (2) compare the
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Mig. 1. Left ventricular thrombus formation on late gadolinium enhancement cardia
asterisk) in the apex of the left ventricle. (B) Late gadolinium enhancement imaging
nfarcted myocardium with areas of microvascular obstruction. LV, left ventricular.
iagnostic accuracy of 2D-echocardiograpy vs. cardiovascular mag-
etic resonance (CMR), and (3) evaluate the course of LV thrombi
n the modern era of primary PCI.
. Methods
The present study is a substudy of the HEBE-trial, which eval-
ated the effects of injection of intracoronary bone-marrow cells
10]. A total of 200 patients presenting with a ﬁrst STEMI was
nrolled in this multicenter study involving 8 high volume primary
CI centers located in the Netherlands. All patients had undergone
rimary PCI with stent implantation within 12 h of symptom onset.
xclusion criteria were: unsuccessful PCI, hemodynamic instabil-
ty, elevation of creatine kinase (CK) or CK-myocardial band <10
imes the local laboratory upper limit of normal, and contraindica-
ions for CMR. The regional committees for medical research ethics
pproved the study protocol and all patients gave informed con-
ent. All patients underwent transthoracic echocardiography (TTE)
nd CMR  at baseline and at 4 months follow-up.
.1. Cardiovascular magnetic resonance
CMR  examinations were performed between 2 and 7 days and
epeated at 4 months after primary PCI. The studies were per-
ormed on a clinical 1.5 T scanner as previously described [10].
hole LV coverage was achieved on cine CMR  with contiguous
hort axis slices using a segmented steady-state free-precession
ulse sequence. Typical in-plane resolution was 1.6 mm × 1.9 mm,
ith slice thickness 5.0–6.0 mm (repetition time/echo time
.2/1.6 ms,  ﬂip angle 60◦, matrix 256 × 156, temporal resolu-
ion 35–60 ms). Late gadolinium enhancement (LGE) images were
btained to examine infarct size, 10–15 min  after administra-
ion of a gadolinium-based contrast agent (Dotarem, Guerbet;
.2 mmol/kg) using a 2D segmented inversion recovery gradient-
cho pulse sequence, with slice position identical to the cine
mages. Typical in-plane resolution was 1.4 mm × 1.7 mm,  with
lice thickness 5.0–6.0 mm (repetition time/echo time = 9.6/4.4 ms,
ip angle 25◦, triggering to every other heartbeat). The CMR  data
as analyzed using a dedicated software package (Mass 2008beta,
eiden). Observers were blinded to echocardiographic results and
atient identity. After endocardial and epicardial borders were
utlined manually on short axis end-diastolic and end-systolic
ine images, left ventricular end-systolic volume (LVESV), and
eft ventricular end-diastolic volume (LVEDV) were determined,
fter which left ventricular ejection fraction (LVEF) and myocar-
ial mass were calculated. Microvascular obstruction (MVO) was
eﬁned as any region of hypoenhancement within the hyperen-
anced infarcted area and was included in the calculation of total
I  size.netic resonance imaging. (A) Cine cardiovascular magnetic resonance of a thrombus
 conﬁrms the avascular non-enhancing thrombus (asterisk) close to the transmural
LV thrombi on CMR  were deﬁned as ﬁlling defects within the
LV cavity, typically adherent to regions of abnormal wall motion
(hypokinesis, akinesis, or dyskinesis) on cine sequences and had to
be conﬁrmed by late gadolinium enhancement (see Fig. 1). Thrombi
were carefully differentiated from regions of MVO  which appear on
LGE as dark areas within the core, and thus completely surrounded,
by the hyper intense acute myocardial infarct. The presence or
absence of LV thrombus on CMR  was scored by two blinded, inde-
pendent, experienced examiners, blinded to patient identity and
TTE results. A consensus was reached in case of disagreement.
2.2. Transthoracic echocardiography
TTE was performed within one day of the CMR  study. Paraster-
nal, apical, and subcostal views were obtained, with special focus
on the apical views, since thrombi are most frequent, although not
exclusively, located at the apex. On TTE, thrombus was deﬁned
as a discrete echo dense structure in the LV cavity with well-
deﬁned margins, distinct from the endocardial border, visible in
both systole and diastole in at least two views and located adja-
cent to a hypokinetic or akinetic area of the LV wall. TTE studies
were independently analyzed from CMR  results. The presence or
absence of LV thrombus on echocardiography was scored by two
blinded, independent, experienced examiners, blinded to patient
identity, and CMR  results. A consensus was reached in case of
disagreement.
2.3. Follow-up
All patients were treated with a loading dose of clopidogrel
300 or 600 mg  and thereafter 75 mg/day in addition to an initial
loading dose of aspirin followed by 80–100 mg/day. Patients were
treated with vitamin K antagonist at the discretion of the treating
physician with a target international normalized ratio of 2.0–3.0 for
≥3–6 months. Patients were seen at the outpatient clinic at 1, 4, 12,
and 24 months after primary PCI, for assessment of clinical status
and adverse events. Stroke was  deﬁned as the new onset of focal
or global neurological deﬁcit caused by ischemia or hemorrhage
assessed by appropriate imaging, e.g., computed tomography or
magnetic resonance imaging, within or around the brain and lasting
for more than 24 h or leading to death. Bleeding was deﬁned accord-
ing to the criteria of the thrombolysis in myocardial infarction trial.
Major bleeding was  deﬁned as a decrease in the hemoglobin level
of >5 g/dl, intracranial hemorrhage or a >15% absolute decrease
in hematocrit, or cardiac tamponade. Minor bleeding was deﬁned
as a decrease in the hemoglobin level of 3 g/dl or >10% decrease
in hematocrit from an identiﬁed site or: >4 g/dl decrease in the
hemoglobin concentration or >12% decrease in hematocrit when
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Table 1
Baseline demographics and characteristics stratiﬁed according to the early, late, or absence of left ventricular thrombus at cardiovascular magnetic resonance imaging (CMR)
in  patients after acute myocardial infarction.
Characteristic Early LV thrombus Late LV thrombusc
Presence (n = 17) Absence (n = 177) p-Value Presence (n = 14) Absence (n = 176) p-Value
Age (years) 57 ± 8 56 ± 10 0.46 57 ± 10 56 ± 9 0.64
Male  gender 14 (82%) 151 (85%) 0.75 13 (93%) 148 (84%) 0.70
Risk  factors
Diabetes mellitus 0 (0%) 12 (7%) 0.60 2 (14%) 10 (6%) 0.22
Known hypertension 4 (24%) 50 (28%) 0.78 4 (29%) 49 (28%) 1.00
Hypercholesterolemia 1 (6%) 37 (21%) 0.20 2 (14%) 36 (20%) 0.74
Current cigarette smoking 6 (35%) 95 (54%) 0.63 6 (43%) 94 (53%) 0.74
Angiography and infarct treatment
Time from symptom onset to PCI (h) 2.8 (2.1–5.1) 3.4 (2.3–4.6) 0.88 2.9 (2.0–5.3) 3.3 (2.4–4.5) 0.83
Anterior infarction 17 (100%) 106 (60%) <0.001 14 (100%) 107 (61%) <0.001
Medication at discharge
Aspirin 17 (100%) 170 (96%) 1.00 13 (93%) 170 (97%) 0.42
Clopidogrel 17 (100%) 177 (100%) 1.00 14 (100%) 175 (99%) 1.00
Coumarin derivate 8 (47%) 23 (13%) 0.001 1 (7%) 31 (18%) 0.47
Medication at 4 months follow-up
Aspirin 17 (100%) 162 (92%) 0.63 13 (93%) 158 (90%) 1.00
Clopidogrel 17 (100%) 150 (85%) 0.48 14 (100%) 150 (85%) 0.22
Coumarin derivate 8 (47%) 27 (15%) <0.001 2 (14%) 34 (19%) 1.00
CMR  (day 2–7)
Presence of microvascular obstructiona 15 (88%) 96 (56%) 0.01 12 (92%) 99 (57%) 0.02
LVEF  (%)a 37 ± 10 43 ± 9 0.10 42 ± 6 43 ± 9 0.68
Infarct  size (g)b 28 ± 12 22 ± 12 0.045 32 ± 8 22 ± 13 <0.001
CMR  (4 months)
LVEF (%)a 43 ± 9 47 ± 9 0.08 42 ± 9 47 ± 9 0.04
Infarct  size (g)b 17 ± 9 14 ± 8 0.20 19 ± 7 14 ± 8 0.02
Data are number (%), mean ± SD or median (25th–75th percentile). LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention.
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ta The analysis included 189 patients.
b The analysis included 167 patients.
c 4 follow-up CMR  were excluded from this analysis due to poor quality.
leeding site is not identiﬁed or spontaneous gross hematuria,
ematemesis, or hemoptysis. A clinical event committee indepen-
ently adjudicated all potential clinical events.
.4. Statistical analysis
Values are reported as mean ± SD or median (25th–75th per-
entile) for continuous variables and as frequency with percentage
or categorical variables. Unpaired Student’s t-test and a Fisher’s
xact test were used to compare differences between groups
f continuous and categorical variables, respectively. To assess
ntraobserver variation, a kappa statistic was calculated for both
MR  and TTE for diagnosing LV thrombus. For inter-observer
ariation, a kappa statistic was calculated from the results from
he ﬁrst examination. Covariates of interest as predictors of LV
hrombus formation were investigated using multivariable logis-
ic regression. Baseline variables that were signiﬁcant at p ≤ 0.10 on
nivariate analysis were entered into a multivariate model. Clinical
vents were presented for descriptive purposes only.
All statistical tests were 2-tailed, and a value of p < 0.05 was
onsidered statistically signiﬁcant. Calculations were generated by
PSS software (version 17.0 for Windows, SPSS, Inc., Chicago, Illi-
ois).
. Results
A total of 6 patients were excluded from this sub-analysis due
o a non-evaluable CMR. In the remaining 194 patients, mean
ge was 56 ± 9 years, 85% of the patients were men, mean base-
ine LV ejection fraction was 42 ± 9% and 90% had TIMI ﬂow
rade 3 after primary PCI. CMR  was performed 4 ± 2 days and
TE 3 ± 2 days after primary PCI. During the 24-month of clinical
bservation, 10 patients were lost to follow-up (all without LV
hrombus on baseline CMR).3.1. Incidence of LV thrombus at baseline and at follow-up
On CMR  at baseline, a thrombus was  found in 17 of 194 (8.8%)
patients. LV thrombus resolution occurred in 15 patients. Two
patients had persistence of LV thrombus on follow-up CMR. On CMR
at four months, a thrombus was  found in an additional 12 patients,
making a total of 14 of 190 (7.4%) patients with LV thrombus (see
Fig. 2). Clinical, angiographic characteristics and CMR  results strati-
ﬁed according to the absence or presence of LV thrombus at baseline
and at 4 months are described in Table 1. All LV thrombi were
seen in patients with anterior infarctions. Patients with both early
and late LV thrombus had more often microvascular obstruction
on baseline CMR  and larger infarct sizes than patients without LV
thrombus formation (see Table 1) In multivariate analysis, throm-
bus formation on baseline LGE was independently associated with,
baseline infarct size (g) (B = 0.02, SE = 0.02, p < 0.001) and anterior
infarction (B = 19.47, SE 4900, p < 0.001). At 4 months, LV thrombus
formation was also independently associated with, baseline infarct
size (g) (B = 0.06, SE = 0.02, p < 0.001).
3.2. CMR vs. TTE for the detection of LV thrombus
Of the 17 thrombi visualized on CMR, 4 were visible also on TTE.
In 9 patients, TTE suggested an apical thrombus, which could not be
conﬁrmed on CMR. Sensitivity and speciﬁcity of baseline TTE com-
pared to baseline CMR  was respectively 21–24% and 95–98% (see
Table 2). CMR  intra- and interobserver variation for the detection
of LV thrombus was   0.91 and  0.96 respectively. TTE intra- and
interobserver variation for the detection of LV thrombus was   0.74
and  0.53 respectively.3.3. Clinical course of LV thrombi
In 8 of the 17 patients with LV thrombus at baseline (Fig. 2), the
treating physician started vitamin K antagonist on top of aspirin
R. Delewi et al. / European Journal of R
Table 2
Sensitivity, speciﬁcity, and predictive value of transthoracic echocardiography (TTE)
compared to cardiovascular magnetic resonance (CMR).
TTE (baseline) CMR  (baseline)
Presence Absence
Presence 4 5
Absence 13 172
Sensitivity = 24%
Speciﬁcity = 95%
TTE (4 months) CMR  (4 months)
Presence Absence
Presence 3 4
Absence 11 172
Sensitivity = 21%
Speciﬁcity = 98%
C
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TMR, cardiovascular magnetic resonance imaging; TTE, transthoracic echocardiog-
aphy.
nd clopidogrel. The other 9 patients were treated with dual anti-
latelet therapy. In 15 of these 17 patients (vitamin K antagonist
herapy: n = 7, no vitamin K antagonist therapy: n = 8), no thrombus
as present at 4 months follow-up (see Fig. 2). Of the two  patients
ith persisting LV thrombus, one was treated with vitamin K antag-
nist therapy. In an additional 12 patients (6.2%) LV thrombus was
bsent at baseline CMR  but occurred at 4 months follow-up. Four
f these patients were on triple-antithrombotic therapy for other
ndications; eight patients were on dual anti-platelet therapy.
.4. Clinical events
One of the 194 patients had clinical evidence of ischemic
troke, however this patient did not have evidence of LV thrombus
ormation on either CMR  or TTE or any other known risk factors
or systemic embolism. In three other patients, gastro-intestinal
Dual anti-platelet 
n=9
CMR and TTE performed 3 
Presence of LV thrombus 
4 months CMR 
n=12 (6.2%)
(TTE=3)
Presence of LV th
4 months C
n=1
(TTE=0)
194 STEMI patients treated b
No Evidence of 
LV thrombus 
baseline CMR 
n=177
(TTE=172)
ig. 2. The course of left ventricular thrombus formation. CMR, cardiovascular magnetic
TE,  transthoracic echocardiography; STEMI, ST-segment elevated myocardial infarction.adiology 81 (2012) 3900– 3904 3903
bleedings were documented; all of them received triple anti-
thrombotic therapy.
4. Discussion
Our study demonstrates an LV thrombus prevalence of 8.8% as
assessed by CMR  among a population of patients with a ﬁrst large
STEMI treated by primary PCI (mean LVEF 42 ± 9%). Routine TTE
had a sensitivity of 21–24% and a speciﬁcity of 95–98% compared to
CMR  for the detection of LV thrombi and the interobserver variation
of TTE was large ( = 0.53). Finally, LV thrombi documented in the
modern era of primary PCI and its concomitant dual anti-platelet
therapy, appear to have a relatively benign course, irrespective of
anti-thrombotic therapy.
4.1. Left ventricular thrombus and incidence
Early data from the pre- and thrombolytic era suggest that in
the setting of acute MI,  LV thrombus may  be present in 7–46% of
patients, most frequently in acute anterior or apical myocardial
infarction [11–13].  In the era of primary PCI and dual anti-platelet
therapy, there is limited data concerning the frequency of LV
thrombus in AMI. In our study, the incidence of LV thrombus was
8.8% in a selected group of ﬁrst STEMI patients treated by primary
PCI as detected on LGE-CMR. Solheim et al. [14], reported a higher
incidence of 15% in the ﬁrst 3 months, Zielinska et al. [15], found LV
thrombi formation in 68 of 1251 patients (5.4%) with acute anterior
wall myocardial infarctions and only in 0.3% in those with non-
anterior wall MI.  Patients with LV thrombus had larger infarct sizes
and were more often anterior MI,  conﬁrming earlier observations
[16,17].
4.2. Left ventricular thrombus and diagnosisAmong the 17 patients with LV thrombus identiﬁed by CMR
in the current study, 4 were visible also on TTE. Sensitivity
and speciﬁcity of baseline TTE compared to baseline CMR  was
therapy Triple antithrombotic therapy, 
including vitamin K 
antagonist 
n=8
.5 +/ - 1.3 days
rombus 
MR
Presence of LV 
thrombus
4 months CMR
n=1
(TTE=0)
y primary PCI 
Presence of
LV thrombus 
baseline CMR 
n=17 (8.8%)
(TTE=4)
 resonance imaging; LV, left ventricular; PCI, percutaneous coronary intervention;
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espectively 21–24% and 97–98%. No independent gold-standard
e.g., histopathology or surgery) was reachable to determine the
etter diagnostics accuracy. However, this discrepancy has been
eported in two  prior studies. One study compared CMR  and LGE
ith echocardiography in a cohort of patients undergoing LV recon-
truction surgery in whom surgical and/or pathology veriﬁcation
f thrombus was uniformly performed [20]. This study reported
hat the sensitivity of TTE was 40%, compared with 88% for CMR,
howing the superiority of CMR. Another study reported an echo
ensitivity and speciﬁcity of 33% and 91% in a heterogeneous pop-
lation of patients with LV systolic dysfunction [16]. Intravenous
cho contrast during TTE may  improve the diagnostic assessment
f LV thrombus [18,19].  However, only one compound (SonoVue,
racco, Milan, Italy) is approved in the Netherlands and its use
s contraindicated by the European Medicines Agency in cardiac
atients with acute coronary syndrome, recent percutaneous coro-
ary intervention, acute or chronic severe heart failure or severe
ardiac arrhythmias.
.3. Left ventricular thrombus and management
Previous studies performed in the pre-thrombolytic and throm-
olytic era reported varying data concerning the risk of future
mbolic events [3–6]. A 1992 meta-analysis included 11 studies
f 856 patients who had an anterior MI;  the odds ratio for an
mbolic event was 5.5 (95% CI 3.0–9.8) [3].  In clinically stable
atients with chronic heart failure, the risk of thromboembolism
eems low (1–3% per year), even in those with very impaired LV
unction and echocardiographic evidence of intracardiac thrombi
21–23]. Our analysis also indicates that documented LV thrombus
by CMR  or TTE) is accompanied by a relative benign course since
one of these patients, irrespective of type of anti-thrombotic reg-
men, experienced a major thrombo-embolic event up to 2 years
fter myocardial infarction.
Whether management of LV thrombus requires vitamin K antag-
nist therapy on top of dual anti-platelet therapy cannot be
oncluded from this observational study and requires the conduc-
ion of a randomized trial in acute MI  patients with LV thrombus.
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